Melanie Cree
Tracked across 3 events · 163 articles · First seen May 12, 2026 · Last active Aug 15, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
A small but growing body of research indicates that GLP-1 drugs, commonly used for obesity and diabetes, may also be effective in treating polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder affecting 1 in 8…
Impact: Lead researcher who conducted three studies on GLP-1 drugs for PMOS, providing key clinical evidence of their efficacy.
Aug 15, 2026 · 12 articles
Tech
Impact: Melanie Cree, MD, PhD, is a professor at the University of Colorado Anschutz and the first author of the report, highlighting her significant contribution to the research and its findings.
Jun 09, 2026 · 6 articles
Tech
Impact: Melanie Cree, a pediatric endocrinology expert at the University of Colorado Anschutz and an author of The Lancet article, supports the name change to Polyendocrine metabolic ovarian syndrome, hoping it will lead to better care and potential research funding.
May 12, 2026 · 145 articles
80
Melanie Cree led studiesGLP-1 drugs show promise for PMOS
ERGEN INTELLIGENCE
Track Melanie Cree live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard